The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Prothrombin Complex Concentrate Market Expected To Change From 2026 To 2030?
The prothrombin complex concentrate market size has experienced strong growth in recent years. It is projected to increase from $1.38 billion in 2025 to $1.48 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. The expansion observed historically can be attributed to an increasing prevalence of coagulation disorders, the development of emergency care infrastructure, the widespread availability of plasma-derived therapies, an uptick in surgical procedure volumes, and the growing use of anticoagulant medications.
The prothrombin complex concentrate market size is anticipated to undergo significant expansion in the coming years, with projections indicating a rise to $1.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This projected growth throughout the forecast period stems from factors such as an escalating demand for swift-acting coagulation treatments, increased investments in the development of recombinant factors, the expansion of facilities for trauma care, a heightened emphasis on patient safety in anticoagulant management, and the broader implementation of standardized bleeding protocols. Prominent trends expected during this period involve the increasing uptake of four-factor PCC products, a rising application of PCC for prompt anticoagulant reversal, an expanding need for solutions in emergency bleeding management, the wider availability of recombinant coagulation products, and a stronger focus on hemostatic therapies that act rapidly.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp
What Primary Drivers Are Shaping The Prothrombin Complex Concentrate Market?
The expanding occurrence of bleeding conditions is anticipated to drive the advancement of the prothrombin complex concentrate market in the future. These medical conditions involve improper blood clotting, resulting in excessive blood loss because of absent or impaired clotting factors or platelets. The rise in bleeding disorders primarily stems from a greater incidence of genetic ailments like hemophilia, more cases of liver disease, increased consumption of anticoagulant drugs, and a higher frequency of vitamin K deficiencies. Prothrombin complex concentrate offers a solution for bleeding disorders by quickly restoring clotting factors, which are crucial for proper blood coagulation and stopping bleeding. As an illustration, a report from the World Federation of Hemophilia, a non-profit organization based in Canada, indicated that in 2023, there were 179,703 reported instances of hemophilia A as of October 2024. Of these, 162,040 cases (90%) were male, 6,990 cases were female, and for 10,673 cases (6%), the patient’s sex was not specified. Consequently, the rising occurrence of bleeding disorders is a key factor propelling the expansion of the prothrombin complex concentrate market.
What Are The Main Segments Within The Prothrombin Complex Concentrate Market Segment Structure?
The prothrombin complex concentrate market covered in this report is segmented –
1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products
2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding
3) By Route Of Administration: Intravenous, Intravenous Infusion Variants, Intravenous Bolus Administration
4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users
Subsegments:
1) By 3-Factor PCC Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)
2) By 4-Factor PCC Typ: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)
3) By Other Products: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products
What Trends Are Affecting The Growth Of The Prothrombin Complex Concentrate Market?
Companies prominent in the prothrombin complex concentrate market are introducing innovative formulations, such as lyophilized powder, to enhance stability, improve storage, and simplify administration. This lyophilized powder is a freeze-dried formulation designed to remove water, thereby increasing shelf life and maintaining potency. This innovation facilitates improved storage conditions and rapid reconstitution for emergency applications. For example, in July 2023, Octapharma USA Inc., a US-based biotechnology firm, received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for the urgent reversal of warfarin in surgeries and invasive procedures. The approval was based on findings from the LEX-209 trial, which reported a 94.6% hemostatic efficacy, proving its effectiveness akin to Kcentra. This development emphasizes the industry’s commitment to advancing coagulation therapies to enhance patient outcomes in critical care settings.
Who Are The Companies Participating In The Prothrombin Complex Concentrate Market?
Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited
Get The Full Prothrombin Complex Concentrate Market Report:
Which Region Accounts For The Largest Portion Of The Prothrombin Complex Concentrate Market?
North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Prothrombin Complex Concentrate Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2026, By The Business Research Company
Proteomics Market Report 2026
https://www.thebusinessresearchcompany.com/report/proteomics-global-market-report
Serine Proteases Market Report
https://www.thebusinessresearchcompany.com/report/serine-proteases-global-market-report
Pruritus Therapeutic Market Report
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model